Physician profile

Atul K Patel

Neurological Surgery · Fairfield, CA

NPI 1740321884

$95,712.13

in general payments reported to CMS, 2019-2025

48 companies · $27K in 2025

The $27K reported for 2025 was more than what 92% of Neurological Surgery providers received nationally (typical 2025 total: $604).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$14,836.10
Consulting Fee$13,000.00
Food and Beverage$4,612.76

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Spineart USA INC $90,600.72 2019-2025 Perla Tl, Perla Tl Mis, Cure Acp
Spineart Sa $1,867.62 2019-2022
Alphatec Spine, INC $459.16 2021-2022
Spineology INC. $355.79 2023 Optimesh Expandable Interbody Fusion System
Integra Lifesciences Corporation $215.28 2021-2023 Codman Certas, Cusa Clarity, Codman Hakim
Neurocrine Biosciences, INC. $187.26 2019-2024 Ingrezza, Ongentys
Orthofix Medical, INC. $184.77 2024 Spinal-Stim, Cervical-Stim
Corelink, LLC $164.69 2022
Pfizer INC. $139.31 2023-2024
Abbvie INC. $131.34 2022-2023
Lundbeck LLC $98.58 2022-2023 Vyepti
Janssen Pharmaceuticals, INC $94.55 2022
Argenx US, INC. $88.35 2023 Vyvgart, Vyvgart Hytrulo
Sk Life Science, INC. $76.08 2023-2024
Revance Therapeutics, INC. $60.64 2024 Daxxify
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Amneal Pharmaceuticals LLC $58.84 2022-2025 Crexont
Genzyme Corporation $58.31 2019-2022
Eisai INC. $58.01 2022-2024
Nevro Corp. $46.19 2019-2020
Teva Pharmaceuticals USA, INC. $44.47 2023-2025 Austedo, Austedo Xr
Integrity Implants INC. $44.42 2019
Medtronic Vascular, INC. $43.80 2019
Lilly USA, LLC $38.71 2023-2025 Kisunla, Amyvid
Jazz Pharmaceuticals INC. $38.08 2024-2025
Merz Pharmaceuticals, LLC $37.16 2022
Tanabe Pharma America, INC. $33.06 2023-2025
Ge Healthcare $31.46 2024
Amgen INC. $28.03 2021
Horizon Therapeutics Plc $27.35 2023 Uplizna
Sanara Medtech INC. $27.23 2024 Celleraterx
Carlsmed, INC. $26.84 2025 Aprevo
Avanir Pharmaceuticals, INC. $25.45 2019
Centinel Spine, LLC $25.30 2019
Supernus Pharmaceuticals, INC. $24.58 2021
Astrazeneca Pharmaceuticals Lp $24.28 2024 Andexxa
Aucta Pharmaceuticals, INC. $23.06 2025 Motpoly Xr
Neurelis, INC. $22.05 2022
Si-Bone, INC. $21.50 2023
Octapharma USA, INC. $21.27 2023 Panzyga
Genentech USA, INC. $21.24 2025 Ocrevus Zunovo
Becton, Dickinson and Company $20.33 2024 Arista Ah Flexitip
Surgalign Spine Technologies, INC. $19.65 2019
Livanova USA, INC. $19.31 2022
Chiesi USA, INC. $17.65 2023 Cleviprex
Allergan, INC. $16.41 2021
Ucb, INC. $16.22 2023
Merck Sharp & Dohme LLC $14.57 2024 Bridion
Electronic Waveform Lab, INC. $13.16 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Atul K Patel

$95,712.13

in general payments reported 2019-2025

Years
2019-2025
Top company
Spineart USA INC
Context
The $27K reported for 2025 was more than what 92% of Neurological Surgery providers received nationally (typical 2025 total: $604).

https://glasscript.com/doctor/78672/atul-k-patel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.